Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

Antonietta CarusoDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy

Chiara BelliaDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy

Alessia PivettiDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy

Luisa AgnelloDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy

Federica BazzaDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy

Concetta ScazzoneDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy

Giulia BivonaDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy

Bruna Lo SassoDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy

Marcello CiaccioDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, ItalyCorrespondence[email protected]

show all

Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

Table 1 Characteristics of patients on CBZ monotherapy, with serum CBZ/CBZ 10,11-epoxide ratio indicated in the basal state and 4 hours after administration of the drug

Table 2 Genotype frequencies for EPHX1 416A>G (A), EPHX1 337T>C (B), and CYP3A422* rs 35599367 (C) in epileptic patients on carbamazepine therapy

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

Figures & data

Table 1 Characteristics of patients on CBZ monotherapy, with serum CBZ/CBZ 10,11-epoxide ratio indicated in the basal state and 4 hours after administration of the drug

Table 2 Genotype frequencies for EPHX1 416A>G (A), EPHX1 337T>C (B), and CYP3A4*22 rs 35599367 (C) in epileptic patients on carbamazepine therapy

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 2 Genotype frequencies for EPHX1 416A>G (A), EPHX1 337T>C (B), and CYP3A422* rs 35599367 (C) in epileptic patients on carbamazepine therapy